<DOC>
	<DOCNO>NCT00940485</DOCNO>
	<brief_summary>This 2 arm study ass efficacy safety Pegasys combination sequential treatment entecavir patient HBeAg positive chronic hepatitis B . Patients pretreated , respond , entecavir 9 36 month randomize one 2 group , receive Pegasys 180micrograms/week sc 48 week + entecavir 0.5mg po daily 8 week , entecavir 0.5mg po daily 48 week . The anticipated time study treatment 3-12 month .</brief_summary>
	<brief_title>A Study Combination Sequential Treatment With PEGASYS ( Peginterferon Alfa-2a ) Entecavir Patients With HBeAg Positive Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Adult patient , &gt; =18 &lt; /= 65 year age HBeAg positive chronic hepatitis B Pretreatment entecavir 936 month Antiviral , antineoplastic immunomodulatory treatment Coinfection active hepatitis A , C D , HIV Evidence decompensated liver disease History evidence medical condition associate chronic liver disease viral hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>